RU2006115615A - Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2 - Google Patents

Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2 Download PDF

Info

Publication number
RU2006115615A
RU2006115615A RU2006115615/14A RU2006115615A RU2006115615A RU 2006115615 A RU2006115615 A RU 2006115615A RU 2006115615/14 A RU2006115615/14 A RU 2006115615/14A RU 2006115615 A RU2006115615 A RU 2006115615A RU 2006115615 A RU2006115615 A RU 2006115615A
Authority
RU
Russia
Prior art keywords
cancer
compound
group
erbb2 kinase
endometrium
Prior art date
Application number
RU2006115615/14A
Other languages
English (en)
Russian (ru)
Inventor
Гарольд Х. ШМИТЦ (US)
Гарольд Х. ШМИТЦ
Original Assignee
Марс, Инкорпорейтед (Us)
Марс, Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Марс, Инкорпорейтед (Us), Марс, Инкорпорейтед filed Critical Марс, Инкорпорейтед (Us)
Publication of RU2006115615A publication Critical patent/RU2006115615A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2006115615/14A 2003-10-10 2004-10-08 Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2 RU2006115615A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51060403P 2003-10-10 2003-10-10
US60/510,604 2003-10-10

Publications (1)

Publication Number Publication Date
RU2006115615A true RU2006115615A (ru) 2007-11-27

Family

ID=34435110

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006115615/14A RU2006115615A (ru) 2003-10-10 2004-10-08 Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2

Country Status (9)

Country Link
US (1) US20050245601A1 (enExample)
EP (1) EP1670455A4 (enExample)
JP (1) JP2007508316A (enExample)
CN (1) CN1889944A (enExample)
AU (1) AU2004280257A1 (enExample)
CA (1) CA2541548A1 (enExample)
IL (1) IL174763A0 (enExample)
RU (1) RU2006115615A (enExample)
WO (1) WO2005034879A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006263669B9 (en) * 2005-06-29 2012-12-13 Mars, Incorporated Inducing peripheral blood vessel vasodilation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2004208B1 (en) * 2005-12-23 2017-01-25 Mars, Incorporated Skin protection and improvement
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
CN1159019C (zh) * 1996-04-02 2004-07-28 火星有限公司 可提取物化合物以及其制备方法和用途
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6207842B1 (en) * 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
US6156912A (en) * 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) * 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers

Also Published As

Publication number Publication date
IL174763A0 (en) 2008-04-13
EP1670455A2 (en) 2006-06-21
JP2007508316A (ja) 2007-04-05
WO2005034879A2 (en) 2005-04-21
AU2004280257A1 (en) 2005-04-21
EP1670455A4 (en) 2008-10-15
US20050245601A1 (en) 2005-11-03
CN1889944A (zh) 2007-01-03
CA2541548A1 (en) 2005-04-21
WO2005034879A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
RU2012140185A (ru) Ингибирование ангиогенеза
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
EA200101046A1 (ru) Производные индигоидных бис-индолов
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
MX2007007598A (es) Macrolidos.
TNSN07294A1 (en) Treatment of metastasized tumors
RU2008150250A (ru) Способ лечения рака
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
JP2007508316A5 (enExample)
RU2009127775A (ru) Способ введения пегилированного липосомального доксорубицина
RU2005129273A (ru) Противораковый агент, содержащий белок lk8 в качестве активного ингредиента
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
RU2011134621A (ru) Возбуждение вазодилатации периферических кровеносных сосудов
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
WO2004081574A3 (en) Detection, monitoring and treatment of cancer
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
Park et al. Anticancer effects of genistein, green tea catechins, and cordycepin on oral squamous cell carcinoma

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090318